Adalvo announces successful DCP Submission for Azelastine+Fluticasone Nasal Spray

Adalvo are pleased to announce our successful DCP submission for Azelastine Hydrochloride/ Fluticasone Propionate 137 microgram/50 microgram Nasal Spray.

Adalvo are pleased to announce our successful DCP submission for Azelastine Hydrochloride/ Fluticasone Propionate 137 microgram/50 microgram Nasal Spray.

The product has been developed in collaboration with one of our strategic partners, based on the reference brand Dymista®. It is used to relieve the symptoms of moderate to severe seasonal and perennial allergic rhinitis, if the use of either intranasal antihistamine or corticosteroid alone is not considered sufficient.

Dymista® nasal spray demonstrated greater nasal symptom relief vs fluticasone propionate, one of the active ingredients in Flonase.

The product sold approximately $237M globally in 2022, according to IQVIA.

This accomplishment enables Adalvo to provide multiple treatment options to both partners and patients, signifying Adalvo's dedication to making a difference in people's lives by bringing high quality generic pharmaceuticals and medicines to market with our commercial partners around the world.

Partner up now!  

At Adalvo, there are no half measures – we are always on target. When your mission is to be faster and stronger than your competitors, you need a winning team driving your vision forward.

ajish.rajan@adalvo.com – Central & Eastern Europe, Russia & CIS
jose.rendueles@adalvo.com- North Europe, APAC, MENA & Israel
margarida.neves@adalvo.com – Brazil
marta.puig@adalvo.com - LATAM (exc. Brazil) & South Europe
paulo.rodriguez@adalvo.com – Europe
supreet.sharma@adalvo.com – UK/Ireland, North America & South Africa
camila.reinoso@adalvo.com - LATAM (exc. Brazil)


arni.baldursson@adalvo.com - Head of Global BD&L

Disclaimer: Products which are subject to patent protection are currently not offered or made available in countries where patents are in force.